Trastuzumab Terminated Phase 2 Trials for Neoplasms Metastasis / Breast Cancer Treatment

TerminatedTreatment2 IdentifierTitleDrugs
NCT00130507Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
NCT00138125Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT01690325Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
NCT00118053Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
NCT00133796Neoadjuvant Herceptin in Patients With Breast Cancer
NCT00088985Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
NCT01290718A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
NCT01363986A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
NCT01928615A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
NCT00674414Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
NCT00453635Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
NCT00824733Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00377780Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer
NCT00427427Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer